new post
StocksRunner logo
mail
search
 
menu
 
Ultragenyx Pharmaceu
$24.80
+0.18%
 
  Set Alerts  
  
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 

RARE Stock Analysis & IQ Rating | Ultragenyx Pharmaceu

 
 

RARE

 

Ultragenyx Pharmaceu

$24.80

 
+$0.04 | +0.18%
 
Set Alerts
 
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 
 
52W High
$46.5
 
 
MKT CAP
$2.39B
 
52W Low
$18.41
 
 
VOL
$2.03M
 
P/E Ratio
N/A
 
 
AVG VOL
$3.53M
 
RSI
46.47
 
 
TREND
Downtrend
 
 
 

RARE Stock IQ

 
lock  Login to see Ultragenyx Pharmaceu (RARE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 

RARE Target Price

 
 
 

Strengths

 
 

RARE Rewards

 Upgraded on attractively valued

RARE Rewards

 Earnings are forecast to grow

RARE Rewards

 Trading below its fair value

RARE Rewards

 Investors confidence is positive

 
 

RARE Price Performance

 
 

$23.11   (+7.31%)

$31.87   (-22.18%)

$31.5   (-21.27%)

$43.62   (-43.15%)

 
 
1year
6month
3month
1month
 

RARE Analysts Opinion

 

Overall standing based on market and analyst consensus. menu Hover over the category for more information

 
 
 

Earnings

×
 

Earnings

 

RARE Earnings Sentiment

 Reported a weak earnings

 
 

Rating

×
 

Rating

 

RARE Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

 

RARE Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

 

RARE Activity Sentiment

 Investors confidence is positive

RARE Activity Sentiment

 Expands stock buyback program

 

Future

×
 

Future

 

RARE Future Sentiment

 Earnings are forecast to grow

RARE Future Sentiment

 Trading below its fair value

 
 

RARE Analysts Opinion

RARE Analysts opinion is negative and it remained unchanged from the past 3 months

 

RARE Street Sentiment

 

Analysts perspectives on the stock desirability, trend direction and growth potential

 
 
100%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
NA
100%
100%
 

RARE Street Sentiment 

RARE Street Sentiment is extremely bullish and have negative views on the near-term outlook

 

RARE Risk Level

 
 

RARE has Low risk level

 
 
 
RARE Risk Level
Low
LOW
HIGH
 

RARE Performance Sentiment

 
Sentiments overview associated with events and the stock performance
 
 
100%
0%
Positive
Negative
8 out of 8
events present
0 out of 8
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 

Key Price Levels

 

Average key support and resistance price levels

 
 
Support
Price
 
$24.07
 
Resistance
Price
 
$19.72
 
 
Current Price Range
 
$29.73
 
 
Show methods +
 
 
 

Analyst Consensus

 

Recent Upgrades and Downgrades

 
 
100%
Buy
Hold
Sell
 
Consensus Rating

STRONG BUY

6
0
0
 

Date

 

Action

 

Rating

 

Firm

Dec 11, 2025

 

Reiterate

 

Buy

 

Citi

 

Nov 25, 2025

 

Reiterate

 

Overweight

 

Barclays

 

Nov 06, 2025

 

Reiterate

 

Buy

 

TD Cowen

 

Sep 30, 2025

 

Reiterate

 

Buy

 

Cantor Fitzgerald

 
 
 
Linked to RARE
Close Price
Change
 

MREO

Mereo BioPharma Group

0.42

-2.54%

 
 
 
RARE Latest Analysis +
 
 
FAQ About RARE Stock Insights
 

What is RARE current stock price?

What are RARE stock strengths?

What is RARE Risk Level?

What is RARE market cap and volume?

What is RARE current Stock IQ?

Should I buy RARE stock right now?

Is RARE a Strong Buy right now?

What does a 'Strong Buy' rating mean for RARE?

What does a 'Strong Sell' rating mean for RARE?

What factors influence RARE's Stock IQ?

 
 
StocksRunner

Explore our RARE Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored RARE Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our RARE Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
 
 

RARE

 

Ultragenyx Pharmaceu

 
Set Alerts
 
 

Current Price

 

$24.80

 
+$0.04 | +0.18%
 
 
52W High
$46.5
 
 
MKT CAP
$2.39B
 
52W Low
$18.41
 
 
VOL
$2.03M
 
P/E Ratio
N/A
 
 
AVG VOL
$3.53M
 
RSI
46.47
 
 
TREND
Downtrend
 
 
 
  Overview  
  
  Comments  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
 
 
 

Linked to RARE

 
 
 
Symbol
Close
Change
 

MREO

Mereo BioPharma Group

0.42

-2.54%

 
 
 
 
 
user
 
 
 
 

RARE Price Performance

 
 

$23.11   (+7.31%)

$31.87   (-22.18%)

$31.5   (-21.27%)

$43.62   (-43.15%)

 
 
1year
6month
3month
1month
 

RARE Analysts Opinion

 

Overall standing per market and analyst expectations. menu Hover over the category for more information

 
 
 

Earnings

×
 

Earnings

 

RARE Earnings Sentiment

 Reported a weak earnings

 
 

Rating

×
 

Rating

 

RARE Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

 

RARE Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

 

RARE Activity Sentiment

 Investors confidence is positive

RARE Activity Sentiment

 Expands stock buyback program

 

Future

×
 

Future

 

RARE Future Sentiment

 Earnings are forecast to grow

RARE Future Sentiment

 Trading below its fair value

 
 

RARE Analysts Opinion

RARE Analysts opinion is negative and it remained unchanged from the past 3 months

 

RARE Street Sentiment

 

Analysts perspectives on the stock desirability, trend direction and growth potential

 
 
100%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
NA
100%
100%
 

RARE Street Sentiment 

RARE Street Sentiment is extremely bullish and have negative views on the near-term outlook

 

RARE Risk Level

 
 

RARE has Low risk level

 
 
 
RARE Risk Level
Low
LOW
HIGH
 
RARE Performance Sentiment
 
Sentiments overview associated with events and the stock performance.
 
 
100%
0%
Positive
Negative
8 out of 8
events present
0 out of 8
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

Key Price Levels

 

Average key support and resistance price levels

 
 
Support
Price
 
$24.07
 
Resistance
Price
 
$19.72
 
 
Current Price Range
 
$29.73
 
 
Show methods +
 
 

Latest Analyst Actions

 

Overall Wall Street Rating

 
 
100%
Buy
Hold
Sell
 
Consensus Rating

STRONG BUY

6
0
0
 
Date
Action
Rating
Firm
 

Dec 11, 2025

Reiterate

Buy

Citi

 

Nov 25, 2025

Reiterate

Overweight

Barclays

 

Nov 06, 2025

Reiterate

Buy

TD Cowen

 

Sep 30, 2025

Reiterate

Buy

Cantor Fitzgerald

 
 
 
 
 
 

RARE Stock IQ

 
 
 
lock  Login to unlock Ultragenyx Pharmaceu (RARE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 
 

Target Price

 
 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 
 

RARE Rewards

 Upgraded on attractively valued

RARE Rewards

 Earnings are forecast to grow

RARE Rewards

 Trading below its fair value

RARE Rewards

 Investors confidence is positive

 
 
 

RARE Latest Analysis

 
 
 

Ultragenyx releases new data on Sanfilippo syndrome gene therapy.

 

Tue Feb 3, 2026

$24.80 | +0.18%
 
Activity

Ultragenyx Pharmaceutical Resubmits BLA For UX111 AAV9 Gene Therapy . (RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) Friday announced that it has resubmitted its Biologics License Application to the United States Food and Drug Administration seeking accelerated approval for UX111 AAV9 gene therapy for the treatment of patients with Sanfilippo syndrome

 

Fri Jan 30, 2026

$24.07 | -0.82%
 
Activity

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). NOVATO Calif. Jan. 23 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases today reported the grant of 16355 restricted stock units of the companys common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of t

 

Fri Jan 23, 2026

$24.21 | +3.46%
 
Activity
 
 
 
 
 
StocksRunner

Discover RARE Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of RARE. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our RARE Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

RARE Stock trends

RARE Stock performance

RARE Stock analysis

RARE investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

RARE Alerts

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental Indicator (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 
 
Cancel
 
×
 
0/666
joker
 
Post
 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing RARE

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing RARE

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.